SKYRIZI RESULTS

SKYRIZI Provides Clinical Remission and Endoscopic Response Results

SKYRIZI achieved both CLINICAL REMISSION and ENDOSCOPIC RESPONSE, as primary measures of three clinical trials. Achieving endoscopic response, also known as endoscopic improvement, means that your doctor can see at least a 50% visible improvement of the intestinal lining.

Before

After


Symptom Relief With SKYRIZI

In clinical trials:

  • SKYRIZI helped to reduce bowel movement frequency and abdominal pain at Week 12
  • A majority of patients on SKYRIZI had significant symptom relief at Week 12 and some had symptom relief as early as Week 4

Patients Experienced Early and Lasting Results on SKYRIZI

Achieved

CLINICAL
REMISSION

meaning few or no symptoms

CD-1 Study at Week 12
600 mg IV

45%

25% placebo

CD-3 Study at Week 52
360 mg/2.4 mL injection

57%

46% placebo

Achieved

ENDOSCOPIC
RESPONSE

meaning at least a 50% visible improvement of the intestinal lining

CD-1 Study at Week 12
600 mg IV

40%

12% placebo

CD-3 Study at Week 52
360 mg/2.4 mL injection

48%

22% placebo

Patients Experienced Early and Lasting Results on SKYRIZI

Achieved

CLINICAL REMISSION

meaning few or no symptoms

CD-1 Study at Week 12
600 mg IV

45%

25% placebo

CD-3 Study at Week 52
360 mg/2.4 mL injection

57%

46% placebo

Achieved

ENDOSCOPIC RESPONSE

meaning at least a 50% visible improvement of the intestinal lining

CD-1 Study at Week 12
600 mg IV

40%

12% placebo

CD-3 Study at Week 52
360 mg/2.4 mL injection

48%

22% placebo

At 12 weeks, in a second induction clinical study (CD-2, n=191) with patients who failed at least one biologic, 42% of patients on SKYRIZI achieved CLINICAL REMISSION vs. 20% on placebo and 29% of patients on SKYRIZI saw ENDOSCOPIC RESPONSE vs. 11% on placebo.

Individual results may vary.

CD-1 (n=336) and CD-3 (n=117) clinical studies were a mixed population of patients with or without prior biologic failure. Patients who achieved a clinical response (CR-100) in the induction studies (CD-1 and CD-2) continued onto the maintenance study (CD-3).